COMPLETED

Narrative Medicine for Improving Well-Being in Patients With Gastrointestinal Cancers

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial assesses whether narrative medicine methods may improve the sense of well-being among gastrointestinal (GI) (digestive system) cancer patients. Narrative medicine is a clinical approach where providers can use a patient's own narrative (perspective) of their illness to promote healing and resilience. By applying narrative medicine's main tool, close reading, to clinical practice, clinicians learn to listen and attend to patients more deeply. This allows for freer communication and the creation of a healthcare encounter that centers on the psychological and emotional well being of the patient in addition to their medical conditions. Narrative medicine can include close reading, creative or reflective writing, and discussion. These methods may help patients with GI cancer to reflect on their life stories, both inside and outside of their illness experience, and help them gather skills to optimize their well-being.

Official Title

Can Narrative Medicine Methods Improve Well-Being in Patients With GI Malignancies

Quick Facts

Study Start:2023-09-27
Study Completion:2025-10-21
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06374251

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with diagnosis of gastrointestinal malignancy actively receiving infusional therapy for cancer.
  2. * Age \>= 18 years.
  3. * English speaking with ability to participate in reading and writing questionnaires and implementation tools.
  4. * Performance Status =\< Eastern Cooperative Oncology Group (ECOG) 3.
  1. * Altered mental status or other cognitive impairment, organic or drug induced that would limit ability to participate in the evaluation.

Contacts and Locations

Principal Investigator

Eve L Makoff, MD
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • Eve L Makoff, MD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-27
Study Completion Date2025-10-21

Study Record Updates

Study Start Date2023-09-27
Study Completion Date2025-10-21

Terms related to this study

Additional Relevant MeSH Terms

  • Malignant Digestive System Neoplasm